C
erebral CMs, also referred to as cavernous angiomas, cavernous hemangiomas, or cavernomas, are vascular malformations consisting of thin hyalinized vascular channels without interposed brain. These lesions are also referred to as angiographically occult vascular malformations due to the fact that they are low-pressure systems that do not shunt blood and are not generally apparent on diagnostic catheter angiography. 8, 29 Prior to the development of MR imaging, diagnosis of CMs was uncommon; only 163 cases had been presented in the literature by 1976, the vast majority of which presented as symptomatic lesions. 54 However, with the ever-increasing availability and fidelity of MR imaging technology, the diagnosis of CMs has become exceedingly more common. Another byproduct of the MR imaging era has been a dramatic increase in the number of CMs being diagnosed prior to symptom onset, with at least 40% of CMs now being identified incidentally. 5 Our ability to make appropriate clinical judgments regarding the management of these lesions is predicated on our understanding of the hemorrhagic and neurological risk associated with CMs and what factors potentially impact this risk. The purpose of this paper is to consolidate the current body of knowledge of the natural history of CMs into a form that helps the cerebrovascular practitioner with patient treatment.
Methods
A literature search using the online database PubMed provided through the National Center for Biotechnology was performed. Search terms were "natural history," "cavernous malformation," "cavernoma," "cavernous angioma," and "cavernous hemangioma." The search was limited to studies in the English language and specific to humans. Articles were reviewed along with any pertinent citations provided by these articles. Studies of interest included those that provided information regarding modes of presentation, hemorrhage rates, and factors affecting prognosis (for example, age, sex, size, and genetic components to the disease).
Epidemiology
Cavernous malformations occur in sporadic and familial forms. 21, 47 They are the second most common vascular lesion behind developmental venous anomalies and account for 10%-15% of all vascular malformations. 5 Based on autopsy and MR imaging studies, the incidence ranges from 0.4% to 0.8%, 5, 34, 42, 48 with 25% of these ocUpdate on the natural history of cavernous malformations and factors predicting aggressive clinical presentation curring in children. 34 The average age of adult presentation is in the 4th or 5th decade of life. Children present in a bimodal pattern with peaks at 0-2 years of age and 13-16 years of age. 34, 41 The familial form of CMs comprises approximately 6%-50% of all cases, and a higher prevalence has been noted in people with Mexican-American ethnicity. Based on current imaging studies, more than 50% of patients with familial CMs have multiple lesions compared with only 12%-20% in those with the sporadic form. 5, 40, 47, 57 In regard to sex, the prevalence of CMs appears equal among men and women. However, some studies (see detailed discussion below) have raised the question of an increased incidence of symptomatic lesions in women. 2, 27, 40, 44, 49, 53, 54 
Presentation
Cavernous malformations have a wide range of presenting symptoms. These can vary from mild symptoms such as headache to more severe symptoms including seizure, focal neurological deficit, and even death. In addition, since the introduction of MR imaging, more and more CMs are being found incidentally. With supratentorial lesions, the most common presenting symptom is new onset seizure, representing 23%-79% of cases. 1, 2, 12, [25] [26] [27] 40, [43] [44] [45] 48, 51, 56, 57 With infratentorial lesions, most patients present with either a focal neurological deficit (for example, cranial nerve palsy, hemiparesis, and hemisensory deficits) or gait ataxia. 20, 30, 44, 52, 55 Brainstem CMs have also been reported to cause symptoms such as cardiovascular instability, respiratory compromise, and hiccups. 55 Cavernous malformations located in the basal ganglia and/or thalamus most commonly present with sensorimotor deficits, but less common presentations of hemiballismus and hydrocephalus have also been reported. 17 All of the above symptoms can be found with or without acute hemorrhage. The definition of hemorrhage varies greatly from study to study, thus creating difficulty in quantifying bleeding rates. Some consider a lesion as having hemorrhaged only when there is a new neurological event in association with positive imaging findings. Others consider only the imaging. Given this, there is a wide range in percentage of patients presenting with hemorrhage, from a low of 9% to a high of 88%. 
Natural History

Overall Hemorrhage Risk
In the early 1990s (corresponding to the increase in MR imaging availability and usage), a rapid increase in the knowledge of the hemorrhage risk associated with CMs occurred. Del Curling et al. 12 were one of the first groups to report on this risk. In their study, MR images from 8000 patients were retrospectively reviewed. Symptoms in these patients included seizure (50%), headache (34%), and focal neurological symptoms (16%). Thirtytwo patients with CMs were identified, for an MR imaging-based incidence of 0.39%. They reported symptomatic hemorrhage rates of 0.25% per patient-year and 0.10% per lesion-year. Robinson et al. 48 retrospectively reviewed MR images from over 14,000 patients. Symptoms in these patients included seizure (52%), focal neurological deficit (46%), headache (30%), and incidental (14%). Sixty-six patients with 76 CMs were identified, for an MR imaging-based incidence of 0.47%. They reported a symptomatic hemorrhage rate of 0.7% per lesion-year. Kim et al. 25 retrospectively reviewed 62 patients with 108 CMs. Most lesions were symptomatic, but 12% were incidental. They reported symptomatic hemorrhage rates of 2.3% per patient-year and 1.4% per lesion-year. Zabramski et al. 57 reported on 21 asymptomatic patients in whom familial CM was diagnosed who were prospectively observed (including serial MR imaging studies) for an average of 2.2 years. They reported symptomatic hemorrhage rates of 6.5% per patient-year and 1.1% per lesion-year. They also identified numerous asymptomatic hemorrhages by MR imaging and calculated asymptomatic hemorrhage rates of 13% per patient-year and 2% per lesion-year. Numerous other natural history studies have been reported over the years, most of which have documented hemorrhage rates ranging from 0.7% to 6% per patient-year (see Table  2 for a complete listing of reported hemorrhage rates).
Risk Factors That Increase Hemorrhage Risk
Hemorrhagic Presentation. Aiba et al. 2 were the first to provide evidence that hemorrhagic presentation negatively impacts the natural history of CMs. In their retrospective review of 110 patients with CMs, they found that patients presenting with hemorrhage were at higher risk for new hemorrhage than those presenting with incidental findings or with seizure (22.9% per patient-year vs 0.39% per patient-year, respectively). Other investigators have documented similar findings. Kondziolka et al. 27 performed a combined retrospective/prospective evaluation of 122 patients with conservatively managed CMs, documenting a symptomatic hemorrhage rate of 0.6% per patient-year in patients without hemorrhagic pre- 40 prospectively evaluated 68 patients with 228 CMs and reported an overall hemorrhage rate of 3.1% per patient-year. While they did not identify hemorrhagic presentation as a standalone risk factor, they did find that patients who presented with hemorrhagic or nonhemorrhagic focal neurological deficits had higher hemorrhage rates than those who presented without focal neurological deficits (8.9% vs 0.4% per patient-year, respectively).
It should be noted, however, that although patients with CMs who present with symptomatic hemorrhage are at an increased risk for new hemorrhage after diagnosis, this period of higher risk appears time limited. This phenomenon, known as "temporal clustering," was suspected by several early clinicians; however, in 2001 Barker et al. 4 provided compelling evidence for temporal clustering when they studied the hazard curve of rehemorrhage for 141 patients with CMs with a history of previous hemorrhage. They noted a spontaneous decline in the hazard risk of CM rehemorrhage approximately 2 years after a previous hemorrhage. Since this report, other investigators have also documented temporal clustering of hemorrhages in patients with CMs. 55 Deep Anatomical Location. In the aforementioned study by Robinson et al., 49 a higher incidence of neurological disability was noted in patients with infratentorial than in those with supratentorial CMs. Similar findings have been noted by other investigators. Porter et al. 43 retrospectively analyzed 173 patients with CM and categorized the CMs by location: 1) infratentorial versus supratentorial, and 2) deep versus superficial (brainstem, thalamus, and basal ganglia CMs were considered deep; the remaining CMs were considered superficial). They reported a higher rate of recurrent symptomatic hemorrhage in infratentorial than in supratentorial lesions (3.8% per patient-year vs 0.4% per patient-year) as well as in deep than in superficial lesions (4.1% per patient-year vs 0% per patient-year). Others provided evidence indicating that brainstem CMs have a particularly poor natural history. Fritschi et al.
14 presented their series of 139 patients with brainstem CMs along with a literature review. They calculated a relatively high symptomatic hemorrhage rate of 2.7% per patient-year and a very high rehemorrhage rate of 21% per patient-year. Porter et al. 44 retrospectively reviewed their experience with 100 patients with brainstem CMs, documenting a symptomatic hemorrhage rate of 5% per patient-year and a symptomatic rehemorrhage rate of 30% per patient-year. Kupersmith et al. 30 retrospectively evaluated 37 brainstem CMs, finding a symptomatic hemorrhage rate of 2.5% per patient-year and symptomatic rehemorrhage rate of 5.1% per patient-year. Kim et al. 25 retrospectively analyzed 62 patients with 108 CMs including 10 whose lesions were located within the brainstem. They found that brainstem CMs had a significantly higher frequency of presenting with a major neurological deficit compared with other lesion locations (80% of brainstem CMs presented with major neurological deficit vs 123% of cortical lesions). Although most studies suggested that brainstem CMs carry higher risk of symptomatic hemorrhage, at least one study by Tarnaris et al. 52 suggests otherwise, as their retrospective analysis of 21 patients with brainstem CMs documented surprisingly low rates of rebleeding and neurological deterioration (0.05% and 0.1% per patient-year, respectively).
Female Sex. Vaquero et al. 53 were one of the first groups to document a female predominance in symptomatic CMs (female/male ratio 2:1). Many studies since have found an increase in the frequency of symptomatic lesions in women. Robinson et al. 48 found a significant increase in hemorrhage rate in females. This was reiterated by studies presented by Aiba et al. 3 and Porter et al. 44 In fact, Porter and colleagues went further to question the effect of pregnancy on hemorrhage risk. Kupersmith et al. 30 found a higher risk of rehemorrhage in women (5.9%) than in men (3.3%). Not all studies, however, have documented a difference in hemorrhage rates between male and female patients. 14, 27, 43 Other Factors Affecting Natural History Seizure. The most common presenting symptom for patients with CMs is seizure (25%-79%). 38, 39 These seizures are thought to be induced by recurrent microhemorrhages from the CM, resulting in perilesional gliosis and inflammation, both of which are epileptogenic.
3 In a retrospective review by Kondziolka et al., 27 4.3% of patients developed new seizures after initial CM diagnosis. In a retrospective review by Del Curling et al., 12 1.5% of patients developed new seizures after initial CM diagnosis. In the retrospective review by Moriarity et al., 40 the risk of developing seizures following CM diagnosis was 2.4% per patient-year for patients not initially presenting with seizures. If the presenting symptom was seizure, the rate of having recurrent seizures was 5.5% per patientyear. While the presumed etiology of seizures in this patient population is recurrent microhemorrhages, there is no evidence to date suggesting that seizure (either at presentation or in follow-up) impacts the risk of CM hemorrhage.
De Novo Formation. Initially it was believed that CMs were developmental anomalies that were present since birth; however, there is now compelling evidence that CMs-in the sporadic and familiar forms-can develop de novo. 22, 47 Several studies have quantified the incidence of de novo CM development, with results ranging from 0.1 to 0.6 new lesions per patient-year. 23, 32, 57 This phenomenon is much more common in the familial than the sporadic forms of the disease, as 27.5%-30% of patients with familial forms develop de novo CM formation while only 4.1% of patients with sporadic lesions develop de novo CM formation over time. 31, 32, 45 Size Dynamics. De novo formation is not the only dynamic aspect of CMs. Lesion size can also vary substantially over time. Pozzati et al. 46 were the first to dem-onstrate the dynamic nature of CMs when they presented 3 cases in which the CM grew substantially over time. They theorized the mechanism to be serial microhemorrhages followed by organization, fibrosis, and calcification. Others have shown that CMs can decrease in size over time. In the retrospective series by Kim et al., 25 the average CM size was 14.2 mm at initial diagnosis and 9.1 mm on repeat imaging. Perhaps the best study demonstrating the dynamic nature of CMs over time is that by Clatterbuck et al. 10 who observed 68 patients with 114 CMs with serial imaging over a mean period of 3.7 years. Over this follow-up period, they found that 22% of lesions were stable in size, 43% of lesions increased in size, and 35% of lesions decreased in size. Many of these lesions had periods of both increase and decrease in size. To date, no study has correlated CM growth with risk of symptomatic hemorrhage.
Familial Inheritance and Genetics. It was long suspected that a genetic link to CMs existed; 7, 9, 24, 28 however, definitive evidence remained elusive until 1982 when Hayman et al. 21 published their seminal paper on CM inheritance. They reported on a kindred of 122 individuals, of whom 5 had cerebral vascular malformations and 3 had CMs. They documented autosomal dominant inheritance with variable expressivity. This report was followed by the studies of Rigamonti et al. 47 and Mason et al. 36 who found that familial inheritance was especially high in Hispanic-American families.
This newly found information provided a patient population through which genetic mapping was used to elucidate the genetic cause of familial CMs. Dubovksy et al. 13 and Gil-Nagel et al. 16 were able to map the responsible gene to 7q. Guenl et al. 18 discovered through analysis of genetic markers a founder mutation among familial and sporadic cases in Hispanic-Americans of Mexican descent, suggesting a common ancestor among these patients. This mutation was later identified as truncating mutations in CCM1. 33 Further studies found that CCM1 was likely not the only responsible gene. 11, 19 Subsequently, Craig et al.
11 discovered 2 additional loci associated with familial CMs, CCM2 on 7p and CCM3 on 3q. They also found that Caucasian forms of familial CMs were 40% linked to CCM1, 20% linked to CCM2, and 40% linked to CCM3. Recent data suggest that a fourth gene may be present.
6,35
The identification of familial inheritance and the genetic mutations that underlie it not only shed light on the underlying molecular mechanisms leading to CM formation, but also impacted clinical management. First, the number of cases of familial CMs appears higher than initially reported, with several studies showing that as many as 50% of patients with CMs have familial inheritance. 33, 47, 57 A detailed family history is therefore imperative when evaluating all patients with CMs, and genetic testing should be considered in those with evidence of familial inheritance. Second, the incidence of CM multiplicity is far higher in familial than in sporadic forms of the disease, with a reported incidence as high as 96% in patients with familial inheritance. 57 Third, the rate of de novo CM formation is much higher in familial than in sporadic forms of the disease. 31, 32, 45 This observation suggests that additional MR imaging studies over time may be appropriate for patients with familial CMs. Finally, familial inheritance appears to have some impact on the risk of hemorrhage. Although no study has thus far documented a higher than expected hemorrhage rate per lesion, the high incidence of CM multiplicity and the high rate of de novo CM formation strongly suggests that the greater overall CM burden in patients with familial forms leads to an increased risk of hemorrhage per patient. Consistent with this notion, annual hemorrhage rates of 4.3% per patient-year have been reported for patients with familial but asymptomatic CMs 31 compared with 0.6% per patient-year for patients with sporadic forms but asymptomatic CMs. 27 Vigilant counseling of familial patients with familial forms regarding the signs and symptoms of hemorrhage is therefore necessary.
Conclusions
Based on our review of the literature, CMs have symptomatic hemorrhage rates ranging from 0.1% to 2.7% per lesion-year and 0.013% to 16.5% per patient-year. Although the hemorrhage rates per patient-year at first appear broad, the majority of studies report rates of hemorrhage that fall within a narrower range of 0.7% to 6% per patient-year. In addition, many studies have identified risk factors that increase the risk of hemorrhage including presenting with a symptomatic hemorrhage, deep or infratentorial location, and perhaps female sex. Seizures are also a significant source of patient morbidity. The reported rates of new seizure following CM diagnosis range from 1.5% to 4.3% per patient-year, and history of a previous seizure increases this rate to 5.5% per patient-year. Finally, available evidence suggests that the greater overall CM burden found in familial versus sporadic forms of CMs leads to a higher annual risk of symptomatic hemorrhage for patients with familial inheritance.
